Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Glycosylated-drug Delivery as Targeted Therapy for Hepatocellular Carcinoma: Are We There Yet?

Author(s): Caecilia H.C. Sukowati*, Gisela Weiz, Witri W. Lestari and Claudio Tiribelli

Volume 29, Issue 31, 2023

Published on: 20 October, 2023

Page: [2439 - 2441] Pages: 3

DOI: 10.2174/0113816128269619231018074301

Price: $65

Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. J Hepatol 2020; 72(2): 342-52.
[http://dx.doi.org/10.1016/j.jhep.2019.09.010] [PMID: 31954496]
[3]
Stockert RJ, Morell AG. Hepatic binding protein: The galactose-specific receptor of mammalian hepatocytes. Hepatology 1983; 3(5): 750-7.
[http://dx.doi.org/10.1002/hep.1840030520] [PMID: 6413351]
[4]
Shi B, Abrams M, Sepp-Lorenzino L. Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem 2013; 61(12): 901-9.
[http://dx.doi.org/10.1369/0022155413503662] [PMID: 23979840]
[5]
Li Y, Huang G, Diakur J, Wiebe L. Targeted delivery of macromolecular drugs: Asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv 2008; 5(4): 299-302.
[http://dx.doi.org/10.2174/156720108785915069] [PMID: 18855599]
[6]
Molejon MI, Weiz G, Breccia JD, Vaccaro MI. Glycoconjugation: An approach to cancer therapeutics. World J Clin Oncol 2020; 11(3): 110-20.
[http://dx.doi.org/10.5306/wjco.v11.i3.110] [PMID: 32257842]
[7]
Weiz G, Molejon MI, Malvicini M, et al. Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver Int 2022; 42(2): 444-57.
[http://dx.doi.org/10.1111/liv.15084] [PMID: 34800352]
[8]
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021; 20(2): 101-24.
[http://dx.doi.org/10.1038/s41573-020-0090-8] [PMID: 33277608]
[9]
Mahmoud K, Swidan S, El-Nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: A comprehensive review on targeting and recent advances. J Nanobiotechnology 2022; 20(1): 109.
[http://dx.doi.org/10.1186/s12951-022-01309-9] [PMID: 35248080]
[10]
Yang S, Cai C, Wang H, et al. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022; 20(1): 26.
[http://dx.doi.org/10.1186/s12964-021-00796-x] [PMID: 35248060]
[11]
Teplensky MH, Fantham M, Poudel C, et al. A highly porous metal-organic framework system to deliver payloads for gene knockdown. Chem 2019; 5(11): 2926-41.
[http://dx.doi.org/10.1016/j.chempr.2019.08.015]
[12]
Hu J, Hu J, Wu W, et al. N-acetyl-galactosamine modified metal-organic frameworks to inhibit the growth and pulmonary metastasis of liver cancer stem cells through targeted chemotherapy and starvation therapy. Acta Biomater 2022; 151: 588-99.
[http://dx.doi.org/10.1016/j.actbio.2022.08.027] [PMID: 36002126]
[13]
Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: State of the art. Signal Transduct Target Ther 2020; 5(1): 101.
[http://dx.doi.org/10.1038/s41392-020-0207-x] [PMID: 32561705]
[14]
Zheng G, Zhao R, Xu A, Shen Z, Chen X, Shao J. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. Eur J Pharm Sci 2018; 111: 492-502.
[http://dx.doi.org/10.1016/j.ejps.2017.10.036] [PMID: 29107835]
[15]
Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 2020; 19(10): 673-94.
[http://dx.doi.org/10.1038/s41573-020-0075-7] [PMID: 32782413]
[16]
Kumar V, Turnbull WB. Targeted delivery of oligonucleotides using multivalent protein-carbohydrate interactions. Chem Soc Rev 2023; 52(4): 1273-87.
[http://dx.doi.org/10.1039/D2CS00788F] [PMID: 36723021]
[17]
Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug. Mol Ther 2020; 28(8): 1759-71.
[http://dx.doi.org/10.1016/j.ymthe.2020.06.015] [PMID: 32592692]
[18]
Springer AD, Dowdy SF. GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther 2018; 28(3): 109-18.
[http://dx.doi.org/10.1089/nat.2018.0736] [PMID: 29792572]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy